Sanofi’s CFO acknowledged setbacks during Paul Hudson’s leadership, which ended abruptly in February after a series of R&D failures, including multiple unsuccessful drug trials. Despite these challenges, the company saw revenue growth from €36 billion in 2019 to €46 billion last year and the development of the high-potential drug Dupixent. As Sanofi prepares for new CEO Belén Garijo, who will focus on enhancing R&D productivity and governance, the company remains committed to its key therapeutic areas amidst ongoing development hurdles, including the recent failure of a meningococcal vaccine in phase 2 studies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fiercebiotech.com/biotech/sanofi-interim-ceo-defends-hudsons-dupixent-legacy-accepts-number-setbacks-rd
